Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteTirzepatide (LY3298176, GIP/GLP-1 RA, TZP) is a dual GIP/GLP-1 receptor agonist. Tirzepatide differentially induces internalization of the GIP and GLP-1 receptors with EC50 values of 18.2 nM and 18.1 nM, respectively.
More Information Supplier PageTirzepatide (LY3298176, GIP/GLP-1 RA, TZP) is a dual GIP/GLP-1 receptor agonist. Tirzepatide differentially induces internalization of the GIP and GLP-1 receptors with EC50 values of 18.2 nM and 18.1 nM, respectively.
More Information Supplier PageTislelizumab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of advanced squamous non-small-cell lung cancer. MW :144.46 KD
More Information Supplier PageTislelizumab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of advanced squamous non-small-cell lung cancer. MW :144.46 KD
More Information Supplier PageTislelizumab (Anti-PDCD1 / PD-1 / CD279) is a monoclonal antibody targeting programmed cell death protein 1 (anti-PD-1). It can be used for the research of advanced squamous non-small-cell lung cancer. MW :144.46 KD
More Information Supplier PageTisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.
More Information Supplier PageTisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.
More Information Supplier PageTisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD.
More Information Supplier PageTisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
More Information Supplier PageTisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
More Information Supplier PageTitanium tetrafluoride is an inorganic compound that is an effective but instable caries preventive agent.
More Information Supplier PageTitanium tetrafluoride is an inorganic compound that is an effective but instable caries preventive agent.
More Information Supplier PageTivantinib is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.
More Information Supplier PageTivantinib is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.
More Information Supplier PageTivantinib is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.
More Information Supplier PageTivozanib is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
More Information Supplier PageTivozanib is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
More Information Supplier PageTivozanib is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.
More Information Supplier PageTizanidine is an imidazoline derivative and a centrally acting α2 adrenergic agonist used as a muscle relaxant for therapy of acute muscle spasms and chronic spasticity.
More Information Supplier PageTizanidine is an imidazoline derivative and a centrally acting α2 adrenergic agonist used as a muscle relaxant for therapy of acute muscle spasms and chronic spasticity.
More Information Supplier PageTizanidine HCl (DS 103-282) is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.
More Information Supplier PageTizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
More Information Supplier PageTJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis.
More Information Supplier PageTJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis.
More Information Supplier PageTJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis.
More Information Supplier PageTJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis.
More Information Supplier PageTJ191 is a selective anti-cancer small molecule that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.
More Information Supplier PageTK216 is a potent inhibitor targeting E26 transformation specific (ETS) factors via blocking the protein-protein interaction with RNA helicases. TK216 exhibits antilymphoma activity.
More Information Supplier PageTK216 is a potent inhibitor targeting E26 transformation specific (ETS) factors via blocking the protein-protein interaction with RNA helicases. TK216 exhibits antilymphoma activity.
More Information Supplier PageTK216 is a potent inhibitor targeting E26 transformation specific (ETS) factors via blocking the protein-protein interaction with RNA helicases. TK216 exhibits antilymphoma activity.
More Information Supplier PageTL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM.
More Information Supplier PageLQP-21 TFA (TLQP-21 Trifluoroacetate) is a VGF-derived peptide that activates the C3aR1 receptor through a folding-upon-binding mechanism.
More Information Supplier PageTLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
More Information Supplier PageTLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
More Information Supplier PageTLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
More Information Supplier PageTLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
More Information Supplier PageTLR2-IN-C29 (C29) is a Toll-like receptor 2 (TLR2) inhibitor that inhibits TLR2/1 and TLR2/6 signaling.
More Information Supplier PageTLR4-IN-C34 (TLR4-C34, C34, TLR4-C34-IN) is a potent and selective antagonist of Toll-like receptor 4 (TLR4). TLR4-IN-C34 reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
More Information Supplier PageTLR4-IN-C34 (TLR4-C34, C34, TLR4-C34-IN) is a potent and selective antagonist of Toll-like receptor 4 (TLR4). TLR4-IN-C34 reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis.
More Information Supplier PageTLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline.TLR7/8 agonist 1 retains TLR7-agonistic activity with an EC50 of 20 nM.
More Information Supplier PageTLR7/8 agonist 1 dihydrochloride is a toll-like receptor TLR7/TLR8 dual-agonistic imidazoquinoline.TLR7/8 agonist 1 retains TLR7-agonistic activity with an EC50 of 20 nM.
More Information Supplier PageTLX agonist 1 (CCRP2, SUN23314) is a modulator of orphan nuclear receptor tailless (TLX, NR2E1) with EC50 of 1.0 μM and Kd of 650 nM. TLX agonist 1 (CCRP2, SUN23314) binds to recombinant TLX protein and enhances TLX transcriptional repressive activity.
More Information Supplier PageTLX agonist 1 (CCRP2, SUN23314) is a modulator of orphan nuclear receptor tailless (TLX, NR2E1) with EC50 of 1.0 μM and Kd of 650 nM. TLX agonist 1 (CCRP2, SUN23314) binds to recombinant TLX protein and enhances TLX transcriptional repressive activity.
More Information Supplier PageTM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM..
More Information Supplier PageTM 5275 sodium is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 6.95 μM..
More Information Supplier PageTM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.
More Information Supplier PageTM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 ranging between 9.7 μM and 60.3 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines.
More Information Supplier PageTMB dihydrochloride (3,3′,5,5′-Tetramethylbenzidine dihydrochloride hydrate, TMB-d, BM blue, Sure Blue TMB) is an excellent colorimetric substrate for detection of horseradish peroxidase (HRP) labeled probes and is used in staining procedures in immunohistochemistry and in enzyme-linked immunosorbent assays (ELISA).
More Information Supplier PageTMB dihydrochloride (3,3′,5,5′-Tetramethylbenzidine dihydrochloride hydrate, TMB-d, BM blue, Sure Blue TMB) is an excellent colorimetric substrate for detection of horseradish peroxidase (HRP) labeled probes and is used in staining procedures in immunohistochemistry and in enzyme-linked immunosorbent assays (ELISA).
More Information Supplier PageTMB-PS (TMBZ-PS, TetraMethyl BisPhenol S, Bis-(2,6dimethyl-4-hydroxyphenyl)-sulfone) is a chromogenic reagent for the detection of hydrogen peroxide e.g. in the enzymatic analysis of body fluids.
More Information Supplier Page
